Lens epithelium-derived growth factor (LEDGF) maintains survival pathways by augmenting the transcription of stress-response genes such as small heat-shock protein 27 . Recently, aberrant expression of LEDGF was found in prostate cancer (PC). Herein, we showed that LEDGF overexpression upregulated Hsp27 in PC cells, DU145, PC-3 and LNCaP and promoted antiapoptotic pathways in PCs. We found that these cells had higher abundance of Hsp27, which was correlated with the levels of LEDGF expression. Transactivation assay in DU145 cells revealed that transactivation of Hsp27 was related to the magnitude of LEDGF expression. Silencing of LEDGF in DU145 cells abrogated Hsp27 expression and inhibited stimulated cell proliferation, invasiveness and migration. These cells were arrested in S and G2 phase, and failed to accumulate cyclin B1, and showed increased apoptosis. Furthermore, LEDGF-depleted DU145 cells displayed elevated Bax and cleaved caspase 9 expression and reduced levels of Bcl2, Bcl-XL . The activated survival pathway(s), ERK1/2 and Akt, were selectively decreased in these cells, which characteristically have lower tumorigenicity. Conversely, the depleted cells, when re-overexpressed with LEDGF or Hsp27, regained tumorigenic properties. Collectively, results reveal the involvement of LEDGF-mediated elevated expression of Hsp27-dependent survival pathway(s) in PC. Our findings suggest new lines of investigation aimed at developing therapies by targeting LEDGF or its aberrant expression-associated stimulated antiapoptotic pathway(s). Cell Death and Disease (2012) 3, e316; doi:10.1038/cddis.2012.57; published online 31 May 2012
Subject Category: Cancer A multi-domain flexible nuclear protein, lens epitheliumderived growth factor (LEDGF), exercises a variety of functions involving cellular abnormalities by interacting with DNA/protein. [1] [2] [3] [4] [5] LEDGF was originally identified as a transcriptional protein that binds to chromatin/DNA 1, 6 mapped to chromosome 9p22.3 genetic locus. 2, 7 Recently, LEDGF has been shown to interact with multiple proteins such as Mycinteracting protein JPO2 8 and mixed-lineage leukemia/menin complex, 9 a domesticated transposase pogo transposable element-derived protein with zinc finger 10 and Cdc7-activator of S-phase kinase (ASK). 11 Furthermore, its helix-turnhelix-like motifs (aa, 421-442 and aa, 471-492) bind to heat-shock element (nGAAn), and N-terminal LEDGF interacts with stress-response elements (nA/TGGGGA/Tn), thereby regulating transcription of small heat-shock proteins (Hsps) such as aB-crystallin and Hsp27 1, 12, 13 and enhancing cell survival. 1, 14, 15 Recently, aberrant expression of LEDGF was found to be involved in development of various types of cancers including subcutaneous angiogenesis and lymphangiogenesis of ovarian carcinoma tumors. 16, 17 More recently, elevated expression of LEDGF was reported in 61% of prostate tumors. 18 Moreover, stress-inducible LEDGF provides cell survival by upregulating Hsp27. 1, 19 Hsp27 belongs to the family of 'survival proteins' and its involvement has been found in a number of cell death pathways induced by cellular and environmental stresses. 20 We posit that LEDGF-mediated overexpression of Hsp27 protein may alter the crucial balance between cell proliferation and cell death, which in turn may lead to cell transformation. Hsp27 can modulate cell proliferation by interacting with the Akt pathway, which has a pivotal role in the survival of many types of cancer cells. [21] [22] [23] [24] [25] As LEDGF is an enhancer of Hsp27, and enhanced expression of Hsp27 is known to be a causative factor in prostate cancer (PC) progression and invasiveness, 26 we hypothesize that LEDGF-induced tumorigenicity may be selectively associated with upregulation of Hsp27-mediated antiapoptotic signaling in PC cells. 27, 28 During carcinogenesis, a large majority of signaling molecules are affected, and their downstream effectors are generally transcription factors. The smaller numbers of these transcription factors may be an ideal target for treating/ postponing cancer formation. 29 Thus, we think that LEDGF should be a potential and promising target for development of transcription-based therapeutics. 30 The RNA interference technology has been shown to be a successful and effective way of inhibiting the synthesis of specific protein. 31 In the current study, we found that expression of LEDGF dramatically elevated in PC cells, DU145, PC-3 and LNCaP. Additionally, we showed that if LEDGF was overexpressed in normal prostate cells, PWR-1E led to transformation, and these cells showed characteristics of cancer cell, DU145. Notably, DU145 cells aberrantly expressing LEDGF or overexpressed with LEDGF displayed enhanced and aggressive characteristic features of tumorigenicity (Figures 8 and 9) . In this work, we provide evidence that knocking down of LEDGF in DU145 by LEDGF-targeted small interfering RNA (siRNA) reduced tumorigenicity, and reduced tumorigenicity was related to reduced expression of Hsp27 and attenuation of Hsp27-mediated survival pathways(s). As a whole, our findings not only offer new perspectives in the modulation of cellular events by LEDGF but also suggest a novel therapeutic target for cancer treatment.
Results
Aberrant expression of LEDGF in human prostate carcinoma cells DU145, PC-3 and LNCaP was associated with increased expression of its downstream target Hsp27. Using an androgen-independent PC cell line DU145 we studied whether increased expression of LEDGF was associated with increased expression of Hsp27 and compared with normal prostate epithelial cell line PWR-1E. (Figure 1b ). Next, we tested whether levels of Hsp27 protein and mRNA were also increased in DU145 cells, as LEDGF is a regulator of Hsp27. Figure 1c (lane 2) and Figure 1d (gray bar) demonstrate that indeed, the levels of Hsp27 were elevated in DU145 cells.
Next, we examined whether the expression of LEDGF was elevated in other androgen-dependent human PC cell lines, PC-3 and LNCaP. As shown in the Figure 1e , these cell lines also harbored elevated LEDGF protein ( Figure 1e , upper panel; lanes 2, 3 and 4). Observed increased levels of Hsp27 in these cell lines ( Figure 1e , middle panel; lane 1 versus 2, 3 and 4) indicating a correlation between LEDGF expression and Hsp27. Furthermore, the expression levels of LEDGF and Hsp27 mRNA were also significantly higher in the PC cell lines (Figure 1f ) as evidenced by real-time PCR. In the current study, we have chosen to perform experiments using normal cells PWR-1E and DU145.
LEDGF overexpression enhanced the transactivation of Hsp27 promoter and increased the migration and invasiveness of DU145 cells. On the basis of our earlier work, 1 we hypothesized that the increased expression of LEDGF may be one factor in the increased Hsp27 expression in DU145 cells. To test this, we first confirmed localization pattern and integrity of ectopically expressed pEGFP-LEDGF in DU145. Figure 2A showed that the ectopically expressed pEGFP-LEDGF protein localized in nucleus. Next, we wished to examine DU145 containing elevated expression of LEDGF, whether these cells overexpressed with LEDGF display further increase in the expression of Hsp27 mRNA. DU145 cells were overexpressed with different concentrations (250, 500 ng, 1 and 2 mg) of pEGFP-LEDGF. Real-time PCR analysis revealed LEDGF concentration-dependent increased expression of LEDGF mRNA ( Figure 2B , black bars) and Hsp 27 ( Figure 2B , gray bars). The increases in Hsp27 mRNA appeared to be associated with the abundance of LEDGF, further supports LEDGF as a regulator of Hsp27.
To examine whether LEDGF transactivated Hsp27 promoter in DU145, cells were co-transfected with varying concentrations of pEGFP-LEDGF or pEGFP-vector and Hsp27-CAT (co-transfection and promoter activity) promoter. CAT values increased significantly with increasing concentration of the LEDGF constructs ( Figure 2C ), indicating that Hsp27 was transactivated by LEDGF.
To determine whether LEDGF overexpression in these cells was functionally involved in enhancing tumorigenicity, cells overexpressing LEDGF were subjected to migration and invasion assays. In the migration assay, confluent and quiescent monolayers of cells were wounded. Photographs were taken 24 h after wounding to observe changes in migration ( Figure 2D ), and the distance of cell migration to the wound area was measured ( Figure 2D right panel) . Cells overexpressing LEDGF were found to have greater migration potential ( Figure 2D ). Also, we observed aggressive invasive behavior in cells overexpressing LEDGF (Figures 8C and Db) . Data analysis revealed that cells ectopically expressed with LEDGF showed B45% increase in invasive behavior in comparison with vector-transfected cells.
Knockdown of LEDGF in DU145 effectively downregulated its downstream target Hsp27. To examine the direct involvement of LEDGF in tumorigenesis, DU145 cells were transfected with siRNA specific to LEDGF (Si-LEDGF) or scrambled siRNA vectors (Si-Control). Stably selected transfectants were examined for LEDGF mRNA (Figure 3a ) and protein (Figure 3b ) by real-time PCR and western blot. The results indicated that cells stably transfected with siRNA LEDGF had significantly reduced expression of LEDGF. Next, we tested whether these cells displayed lower expression of Hsp27 by performing western analysis using anti-Hsp27 antibody. Data revealed that reduced expression of Hsp27 was associated with LEDGF expression level (Figure 3c ). To rule out the down regulation of Hsp27 expression is specific to LEDGF depletion, and not due to nonspecific silencing effects of siRNA used against LEDGF, we reprobed the membrane with specific antibodies for other proteins such as Sp1, Prdx6 and b-actin (Figure 3c ). Densitometry of immunoblots disclosed no change in the expression pattern of Sp1 or Prdx6 or b-actin, suggesting that Si-LEDGF specifically depleted LEDGF. To examine further whether Si-LEDGF reduced promoter activity of Hsp27, we performed transactivation assay. We found that Si-LEDGF cells displayed reduced Hsp27 promoter activity compared with Si-Control cells (Figure 3d , open bar versus gray bar).
Furthermore, it is known that activated STAT3 upregulates Hsp27 and facilitate phosphorylation of Hsp27 at serine residue 78 and aberrant STAT3 signaling induces cell malignancies. We, therefore, next examined the level of STAT3 expression in LEDGF-depleted cells. We could observe a reduced level of total (Figure 3e Knockdown of LEDGF induced S-phase and G2-M arrest through downregulation of cyclin B1 in DU145 cells. To characterize the process of inhibition of proliferation of Si-LEDGF-DU145 cells, we analyzed the cell cycle progression by FACS analysis as described elsewhere. 32 As shown in 
Role of LEDGF in prostate cancer B Bhargavan et al we confirmed the LEDGF silencing ( Figure 9Aa ) and its dose-responsive effect on Hsp27 expression (Figure 9Ab ). The same membrane was reprobed with ERK and Akt antibodies specific to phosphorylated or non-phosphorylated forms. Interestingly, we could observe reactivation of both ERK1/2 ( Figure 9Ac , right panel; lanes 2 and 3) and Akt ( Figure 9Ae , right panel; lanes 2 and 3) proteins, indicating involvement of LEDGF in PC progression is through Hsp27-ERK/Akt signaling. Next, we became interested to know whether aboveobserved events, reactivation of ERK1/2 and Akt may also reverse its viability, proliferation and migration behaviors. We found that indeed, the overexpression of Hsp27 in LEDGFdepleted cells, significantly reversed its viability ( Figure 9B ), proliferation ( Figure 9C ) and migratory behavior (Figure 9Dh , i, k and l). Conversely, Si-Control cells overexpressed with Hsp27 further enhanced its proliferation ( Figures 9A and B) and migratory behavior (Figures 9Db, c, e and f) .
Ectopic expression of LEDGF in normal prostate epithelial cells, PWR-1E, transformed them into invasive cells. To determine whether normal prostate cells overexpressing LEDGF initiate tumorigenesis, we transfected PWR-1E cells with 1 mg of pEGFP-LEDGF ( Figure 10A ). The ectopic expression of LEDGF enhanced the survival ( Figure 10B ) and proliferation ( Figure 10C ) of these cells as evidenced by viability (MTS) and BrdU assays. Furthermore, in a parallel experiment, these cells were also used for invasion assay. Data showed an induction of invasiveness in these cells (Figures 10D and Eb) .
Discussion
Our present work showed that androgen-independent DU145 and androgen-dependent PC-3 and LNCaP PC cell lines tested using expression analysis displayed aberrant expression of LEDGF and Hsp27. Importantly, the expression level of Hsp27 was well correlated with abundance of LEDGF protein. We also found that normal cells, PWR-1E when overexpressed with LEDGF led to expression of tumorigenic property, arguing that LEDGF overexpression causes initiation of tumorigenesis ( Figures 10D and E) . Furthermore, DU145 having aberrant expression of LEDGF when overexpressed with LEDGF revealed more aggressive tumorigenic properties (Figure 2 ). In the above scenario we concluded that transcriptional protein LEDGF is a crucial factor required for progression and initiation of tumorigenesis. LEDGF achieved this by upregulating Hsp27, and thereby stimulating the survival signaling Akt/ERK pathway(s). Effective knockdown of LEDGF in DU145 cells, abolished its tumorogenic properties through downregulation of Hsp27 and deactivation of ERK/Akt proteins. Interestingly, LEDGF- (Figure 9 ), supporting the hypothesis that LEDGF has its role in cancer progression through the upregulation of Hsp27. Hsp27 has been reported to interact with STAT3, a crucial transcription factor implicated in the maintenance and antiapoptotic status of cancerous cells. 33, 34 We found that LEDGF-depleted cells exhibited reduced level of STAT3 and phosphorylated forms (Figure 3e) .
Furthermore, LEDGF has recently attracted attention owing to its frequent aberrant expression in tumor cells, and to its cytoprotective and chemoresistance properties. 30 Our data showed that it is possible to markedly reduce the expression of LEDGF in DU145 cancer cells and its tumorigenicity/ metastasis, by the use of Si-LEDGF ( Figure 7E ). Furthermore, the increased LEDGF expression in prostate tumors and BPH compared with normal prostate tissue suggests that this protein might be upregulated during prostate carcinogenesis or development of inflammatory conditions of the prostate. 18, 30 Its relatively high expression in prostate tumors and their adjacent 'normal' tissue is likely induced by inflammation and oxidative stress, key factors underlying prostate carcinogenesis. 35 Inflammation and oxidative stress are associated with development of BPH, which may explain our observation that LEDGF is also strongly expressed in 
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Relative Density (pixels) Figures 7B-D) . Moreover, Hsp27 is a stress-induced molecular chaperone that is highly expressed in castrate-resistant PC and other cancers, and is often associated with metastasis and poor prognosis. 36 In the present study, we observed that LEDGF was aberrantly expressed, and the transactivation of LEDGF promoter was much higher in human prostate carcinoma cells, DU145. Interestingly, the effective depletion of LEDGF resulted in a decreased level of Hsp27 and promoter activity in these cells. However, the effective knockdown of LEDGF in DU145 cells led to a significant decrease in their proliferation rate as evidenced by BrdU assay (Figure 3 ) and delayed monolayer confluency. Overexpression/re-overexpression of LEDGF significantly increased the proliferative property and viability in these cells as examined by BrdU and MTS assays, respectively, emphasizing the indispensable role of LEDGF in controlling cell proliferation. Also, the knockdown of LEDGF reversed the apoptotic signaling in cancer cells, as shown by an increase in Bax and cleaved caspase 9 expression and downregulation of procaspase 9, Bcl2 and Bcl-xL proteins ( Figure 6D ). Initiation of mitosis is known to be regulated by the activation of cdc2-cyclin B complex. 37 Although we could not show that cyclin B1 is the direct target of LEDGF, we did observe that silencing of LEDGF induced activation of the Role of LEDGF in prostate cancer B Bhargavan et al apoptotic signaling and S-phase and G2-arrest of the cells significantly (Figure 5a ). However, we can expect more remarkable and noticeable results following synchronization of cells. However, in present study, we followed the methods of Long et al., 32 to produce natural and bona-fide outcomes. We think that synchronization of cells is not feasible or cumbersome to occur in body's natural cellular microenvironment. However, in a previously published study, LEDGF was found to interact with the S-phase kinase (Cdc7:ASK) during cell cycle progression. It is well known that in higher eukaryotic cells, cyclin B1 is excluded from the nucleus by its NESdependent transport mechanism during interphase, and that NES-mediated export of proteins from the nucleus, including cyclin B1, has a role in the DNA damage-induced G2 checkpoint. Our results in this study suggest that the failure to detect cyclin B1 in the nuclear fraction of siRNA-transfected cells may be due to its DNA damage-induced G2 checkpoint. Hsp27 is also involved in the regulation of Akt, inhibiting Bax activation to enhance cell survival. We found that silencing of the LEDGF gene deactivated these two important signaling molecules. However, in this work we could be able to demonstrate the efficiency of Si-LEDGF in blocking or reducing growth and proliferation of PC cells in vitro and inhibiting progression of tumorigenic properties of PC cells. Our results from cell viability (MTS assay) and proliferation (BrdU assay) coupled with migration and invasion assays suggest that LEDGF may have role in cancer proliferation. Targeting LEDGF knockdown strategy may be useful tool to suppress growth of PC cells. Furthermore, BrdU incorporation and cell cycle assays revealed that Si-LEDGF delivery to DU145 cells induces cell arrest at G2 level or their progression, and that in turn leads to apoptotic cell death.
In conclusion, we demonstrated, for the first time, that the underlying mechanism involved in LEDGF deficiency blocks carcinogenesis by suppressing Hsp 27-ERK1/2 and Akt pathways in human PC cells DU145. Certainly, more work is needed for a full understanding of the role of LEDGF in PC. However, we were able to show that LEDGF knockdown should be an effective strategy in developing more effective 
Materials and Methods
Cell lines. Human prostate adenocarcinoma cell lines DU145, PC-3 and LNCaP were used in the present study. Observations were compared with normal prostate epithelium cell line PWR-1E wherever necessary. All the cell lines were obtained from the American Tissue Culture Collection (Bethesda, MD, USA). The DU145 cells were cultured at 37 1C in a 5% CO 2 atmosphere in minimum essential medium (MEM) (Gibco-BRL, Bethesda, MD, USA) supplemented with 10% heatinactivated fetal calf serum (FCS). The MEM also contained 1 mM L-glutamine, 25 mM Hepes, 100 unit/ml penicillin and 100 mg/ml streptomycin. The PWR-1E cells were cultured in Keratinocyte serum-free medium supplemented with growth factors (Gibco-BRL). PC-3 and LNCaP cells were maintained in RPMI medium supplemented with 10% heat-inactivated FCS, 1 mM L-glutamine, 25 mM Hepes, 100 unit/ml penicillin and 100 mg/ml streptomycin.
Real-time PCR. Total RNA was extracted from cells using TriZol Reagent (Invitrogen, Carlsbad, CA, USA), and was used for first-strand DNA synthesis using SuperScript II (Invitrogen Construction of Hsp27-CAT and EGFP-LEDGF constructs. Hsp27-CAT construct was engineered as described previously. 13 Briefly, a forward primer containing a SacI site (5 0 -GCGTCGAGCTCTCGAATTCATTT GCTT-3 0 ) and reverse primer with a XhoI site (5 0 -GCTCTCGAGGTCTGCTCAGAA AAGTGC-3 0 ) were used to generate the fragment, which was cloned between the EcoRI sites of the TA vector (Invitrogen). The Hsp27-TA construct was digested with SacI and XhoI and promoter fragments was ligated to pCAT-Basic vector (Promega, Madison, WI, USA). A construct containing a green fluorescent protein (GFP) and LEDGF cDNA was generated with the 'living color system' (Clontech, Palo Alto, CA, USA) using the plasmid vector pEGFP-C1 (Clontech) for LEDGF protein overexpression studies. Expression construct, pCMV-Hsp27 and empty vector, pCMV-V, were purchased from Addgene (Cambridge, MA, USA).
CAT assay. The CAT assay was performed using a CAT-ELISA kit (Roche Diagnostics GmbH). Cells were transfected/co-transfected with reporter construct (Hsp27-CAT) and/or EGFP-LEDGF/Si-LEDGF expression vectors. After 48 h of incubation, cells were harvested, and extracts were prepared and protein was normalized. CAT-ELISA was performed to monitor CAT activity, following the manufacturer's protocol. Absorbance was measured at 405 nm using a microtiter plate ELISA reader. Transactivation activities were adjusted for transfection efficiencies using GFP or SEAP values. The transfection experiments were carried out either with Superfactamine Reagent (Invitrogen) or using Neon Transfection system (Invitrogen).
siRNA assay. The LEDGF-specific siRNA expression plasmid was designed according to the method described earlier. 39 The sequence was selected from location 1340-1360 (5 0 -AAAGACAGCATGAGGAAGCGA-3 0 ). The sense and antisense oligonucleotides with the internal loop were synthesized by Invitrogen. These were annealed and ligated into the BamHI and HindIII sites of pSilencer 4.1-CMV hygro (Ambion, Carlsbad, CA, USA). pSilencer 4.1-pCMVhygro expressing a scrambled siRNA (Ambion) was used as a control. siRNA constructs were transfected into DU145 cell with Superfactamine Reagent (Invitrogen). At 24 h after transfection, stable transfected cells were selected using 400 mg/ml of hygromycin (Invitrogen) over a period of 9 days. Silencing was confirmed by LEDGF mRNA and protein expression.
BrdU incorporation and MTS assay. Cell proliferation assay was performed with BrdU incorporation assay kit according to manufacturer's protocol (Roche Diagnostics GmbH). Briefly, equal number of cells was seeded in 96-well plates at a density of 5000 cells/well. Following incubation cells were labeled with BrdU for 2 h, the OD was measured at 450 nm. MTS assay performed to measure the viability of the cells at different time points. In brief, 5000 cells/well were seeded into 96-well plates. Following incubation with MTS dye, absorbance was measured at 490 nm.
Flow cytometry for cell cycle and apoptosis. Scrambled Si-Controland Si-LEDGF-transfected cells were grown in T75 culture flask. After 24 h, cells were harvested, fixed with 5 ml of ice-cold 70% ethanol (4 1C). Cell pellets were collected by centrifugation and resuspended in 400 ml of PBS, 50 ml of propidium iodide (PI) solution (0.6 mM) and 50 ml of RNaseA (1 mg/ml). After 30 min cells were analyzed for DNA content using a FACS flow cytometer. Fluorescence from the PI-DNA complex was estimated on a minimum of 20 000 cells per sample and analyzed with CellQuest Pro software.
TUNEL assay. Si-LEDGF-and scrambled Si-Control-transfected cells were seeded onto coverslips and incubated for 24 h. TUNEL staining (in situ cell death detection kit, Roche Diagnostics GmbH) and staining with 4 0 ,6-diamidino-2-phenylindole dihydrochloride (DAPI) (Dojindo Laboratories, Kumamoto, Japan) were performed. The percentage of TUNEL-positive cells per total number of cells was counted from the number of DAPI-stained nuclei in six different fields of each slide for each group using the image analyzing software.
Wound-healing assay. Si-LEDGF-transfected and Si-Control-transfected cells or pEGFP-V or pEGFP-LEDGF-transfected cells were seeded into 60-mm dishes at 1.5 Â 10 6 cells. The confluent cell monolayer was scraped with a sterile pipette tip with a fixed diameter. For each dish, three-five wounds were made, and three sites of regular wounds were selected and marked. Wounded monolayers were then washed three times with PBS to remove cell debris. Cells were permitted to migrate into the area of clearing for 24 h. Immediately after wounding and at the end of the experiment (after 24 h), wounds were photographed and semiquantitative measurements of wounds were taken. A mean width was determined, and the average width of wound closure was calculated as described previously.
Cell invasion assay. Invasion assay was performed with Cytoselect TM 96-well cell invasion assay (Cell Biolabs, INC., San Diego, CA, USA) according to manufacturer's instructions. Briefly, around 2 Â 10 6 cells per well of both SiControl and Si-LEDGF or pEGFP-V-or pEGFP-LEDGF-transfected cells were resuspended in serum-free MEM medium, and were seeded into the extracellular matrix layer, which had been previously rehydrated at room temperature for 1-2 h. MEM media of 150 ml containing 10% fetal bovine serum was added to the lower chamber as chemo attractant. Cells were incubated for 24 h at 37 1C in a CO 2 incubator (5% CO 2 ). Invaded cells on the bottom of the insert membrane were dissociated from the membrane by incubation with cell detachment buffer and subsequently lysed and detected by CyQuant GR dye. The fluorescence was quantified with a fluorescence plate reader using a 480/535-nm filter set. Percent invasion index was calculated by normalizing the fluorescence reading of invaded cells with total cell fluorescence reading. Invaded cells on the membrane were photomicrographed under fluorescent microscope from each set of experiments, by fixing the membrane in methanol and then stained with CyQuant GR dye.
Statistical analysis. All the statistical analyses were done in Graphpad Prism software (La Jolla, CA, USA). Comparison between two groups were done with student t-test. Multiple comparisons were done by ANOVA. A P-value of o0.01 and o0.001 was defined as indicating a statistically significant difference.
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